Exclusive

Publication

Byline

Singapore Clinical Trial: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderate to Severe Hidradenitis Suppurativa

Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety o... Read More


Singapore Clinical Trial: A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Parti... Read More


Singapore Clinical Trial: Prospective randomised controlled evaluation of Tetracycline ointment for preventing infections in uncomplicated soft-tissue wounds repaired in the emergency department – a pilot study.

Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'Prospective randomised controlled evaluation of Tetracycline ointment for preventing infections in u... Read More


Singapore Clinical Trial: Role of glucagon-like peptide 1 receptor Agonist (GLP1 RA) Dulaglutide on cerebral hemodynamics In patients with severe and symptomAtic steNosis of inTracranial internal carotid artery or middle cerebral artery with impaired cerebral vasodilatory reserve- an open-label randomised clinical trial (RADIANT)

Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'Role of glucagon-like peptide 1 receptor Agonist (GLP1 RA) Dulaglutide on cerebral hemodynamics In p... Read More


Singapore Clinical Trial: A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the effica... Read More


Singapore Clinical Trial: A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Singapore, May 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adi... Read More


Two Generations, One Mission: How 'Forest Traiil' is Turning Forgotten Roots into a Modern Health Revolution

New Delhi, May 6 -- Go Green Spices Pvt Ltd launchesForestTraiil,apremium natural foods brand offering Vedic nutrition, BilonaA2 Ghee,and raw wildforesthoney formodernconsumers in Indiaand beyond.... Read More


Muharraq Governor honours partners of first phase of a safety campaign

Bahrain, May 6 -- Muharraq Governor Salman bin Isa Bin Hindi Al Mannai praised the success achieved by the first phase of the awareness campaign "For Your Safety... Awareness is Your Security", affirm... Read More


Nigerian artist Omofemi's portrait of Prince William draws global attention [PHOTOS]

Nigeria, May 6 -- A Nigerian visual artist, Oluwole Omofemi, has drawn international acclaim following the unveiling of a new portrait of Prince William. The painting, commissioned by the British lif... Read More


Midal Cables reinforcing its ESG-driven operational excellence, launches ESG Report

Bahrain, May 6 -- Midal Cables has announced the launch of the third edition of its Sustainability Report, marking another milestone in the Group's structured approach to responsible growth and long-t... Read More